Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHL7OB)

• Drug Name: Uracil mustard Drug Info
• Synonyms: Chlorethaminacil; Demethyldopan; Desmethyldopan; Nordopan; Uracillost; Uracilmostaza; Uramustin; Uramustina; Uramustine; Uramustinum; Aminouracil mustard; Uracil lost; Uracil lost [German]; Uracil mustard [USAN]; Uracil nitrogen mustard; ENT 50439; U 8344; CB-4835; SK-19849; U-8344; Uracil mustard (TN); Uracil mustard (USAN); Uramustina [INN-Spanish]; Uramustine (INN); Uramustinum [INN-Latin]; URACIL MUSTARD (500 MG) (FOR U.S. SALE ONLY); 2,6-Dihydroxy-5-bis(2-chloroethyl)aminopyrimidine; 2,6-Dihydroxy-5-bis[2-chloroethyl]aminopyrimidine; 5-(Bis(2-chlorethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)-2,4-(1H,3H)pyrimidinedione; 5-(Bis(2-chloroethyl)amino)uracil; 5-(Di-(beta-chloroethyl)amino)uracil; 5-(Di-2-chloroethyl)aminouracil; 5-Aminouracil mustard; 5-N,N-Bis(2-chloroethyl)aminouracil; 5-[Bis(2-chlorethyl)amino]-2,4(1H,3H)pyrimidinedione; 5-[Bis(2-chloroethyl)amino]uracil; 5-[Di(2-chloroethyl)amino]uracil; 5-[Di(beta-chloroethyl)amino]uracil; 5-[Di(beta.-chloroethyl)amino]uracil; 5-[bis(2-chloroethyl)amino]-1H-pyrimidine-2,4-dione; 5-[bis(2-chloroethyl)amino]-2,4(1H,3H)-pyrimidinedione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4(1H,3H)-dione; 5-[bis(2-chloroethyl)amino]pyrimidine-2,4-diol

Indication

Disease Entry	ICD 11	Status	REF
Acute myeloid leukaemia	2A60	Approved	[1] , [2] , [3]

• Therapeutic Class: Anticancer Agents
• Cross-matching ID:
  PubChem CID: 6194
  ChEBI ID: CHEBI:9884
  CAS Number: CAS 66-75-1
  TTD Drug ID: DMHL7OB

Molecule-Related Drug Atlas

Drug(s) Targeting Human Deoxyribonucleic acid (hDNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cisplatin	DMRHGI9	Solid tumour/cancer	2A00-2F9Z	Approved	[5]
Oxaliplatin	DMQNWRD	Colorectal cancer	2B91.Z	Approved	[6]
Daunorubicin	DMQUSBT	Acute myeloid leukaemia	2A60	Approved	[7]
Ifosfamide	DMCT3I8	Solid tumour/cancer	2A00-2F9Z	Approved	[8]
Cyclophosphamide	DM4O2Z7	Solid tumour/cancer	2A00-2F9Z	Approved	[9]
Carboplatin	DMG281S	Ovarian cancer	2C73	Approved	[10]
Busulfan	DMXYJ9C	Myeloproliferative syndrome	2A22	Approved	[11]
Procarbazine	DMIK367	Hodgkin lymphoma	2B30	Approved	[12]
Dactinomycin	DM2YGNW	Solid tumour/cancer	2A00-2F9Z	Approved	[13]
Dacarbazine	DMNPZL4	Melanoma	2C30	Approved	[14]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Human Deoxyribonucleic acid (hDNA)	TTUTN1I	NOUNIPROTAC	Modulator	[4]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7621).
• [2] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Excision of DNA adducts of nitrogen mustards by bacterial and mammalian 3-methyladenine-DNA glycosylases. Carcinogenesis. 1996 Apr;17(4):643-8.
• [5] Cisplatin and DNA repair in cancer chemotherapy.Trends Biochem Sci.1995 Oct;20(10):435-9.
• [6] Structures of oxaliplatin-oligonucleotide adducts from DNA.J Mass Spectrom.2012 Oct;47(10):1282-93.
• [7] 31P NMR spectra of ethidium, quinacrine, and daunomycin complexes with poly(adenylic acid).poly(uridylic acid) RNA duplex and calf thymus DNA. Biochemistry. 1989 Apr 4;28(7):2804-12.
• [8] Pharmacokinetics and metabolism of ifosfamide in relation to DNA damage assessed by the COMET assay in children with cancer. Br J Cancer. 2005 May 9;92(9):1626-35.
• [9] O6-methylguanine-DNA methyltransferase activity and sensitivity to cyclophosphamide and cisplatin in human lung tumor xenografts. Int J Cancer. 1998 Sep 11;77(6):919-22.
• [10] Inhibition of carboplatin-induced DNA interstrand cross-link repair by gemcitabine in patients receiving these drugs for platinum-resistant ovarian cancer.Clin Cancer Res.2010 Oct 1;16(19):4899-905.
• [11] DNA intrastrand cross-link at the 5'-GA-3' sequence formed by busulfan and its role in the cytotoxic effect. Cancer Sci. 2004 May;95(5):454-8.
• [12] Brca2/Xrcc2 dependent HR, but not NHEJ, is required for protection against O(6)-methylguanine triggered apoptosis, DSBs and chromosomal aberrations... DNA Repair (Amst). 2009 Jan 1;8(1):72-86.
• [13] Structural studies of atom-specific anticancer drugs acting on DNA. Pharmacol Ther. 1999 Sep;83(3):181-215.
• [14] Predicting the myelotoxicity of chemotherapy: the use of pretreatment O6-methylguanine-DNA methyltransferase determination in peripheral blood mono... Melanoma Res. 2011 Dec;21(6):502-8.